Today: 20 May 2026
Buffett era ends: Berkshire Hathaway (BRK.B) stock dips as Greg Abel takes over
1 January 2026
2 mins read

Buffett era ends: Berkshire Hathaway (BRK.B) stock dips as Greg Abel takes over

NEW YORK, January 1, 2026, 08:11 ET — Market closed

Berkshire Hathaway’s Class A and Class B shares closed slightly lower on Dec. 31, Warren Buffett’s final day as chief executive, before vice chairman Greg Abel takes over on Jan. 1. Class A shares slipped $600, or 0.1%, to $754,800 and Class B shares fell $1.06, or 0.2%, to $502.65. Berkshire ended September with $381.7 billion of cash and equivalents and a $283.2 billion stock portfolio led by Apple and American Express, and it has not said who will run that portfolio after Todd Combs left for JPMorgan Chase.

That transition is one of the biggest handovers on Wall Street, removing the CEO title from the investor who became Berkshire’s decision-making center of gravity for decades. The market reaction was restrained, but the questions are not.

Abel inherits a sprawling set of businesses and a balance sheet that gives him room to wait for opportunities or move quickly when markets dislocate. Investors will judge him on capital allocation — plain English for how he spends the company’s money — and on whether Berkshire’s trademark patience survives a change at the top.

U.S. equities markets are closed on Thursday for New Year’s Day, and Berkshire will next trade when the NYSE reopens on Friday. The holiday pause means the first market verdict on Abel’s CEO era comes a day late.

Buffett, 95, will remain chairman and has signaled he plans to keep showing up. “I’m not going to sit at home and watch soap operas,” Buffett said, according to People. People

Abel is best known inside Berkshire for running operations rather than picking stocks, having overseen non-insurance businesses for years. Berkshire’s model is deliberately decentralized, leaving most day-to-day decisions with unit managers.

The company’s earnings engine spans Geico insurance, the BNSF railroad and a long list of manufacturing, energy and retail businesses. Its insurance “float” — premiums held before claims are paid — has long supplied investment capital.

With interest rates still central to investment income, the return on cash matters more than when yields hovered near zero. Investors will also watch for share repurchases, or buybacks, which reduce the share count and can lift per-share results when management believes the stock is undervalued.

Berkshire’s slight decline in the final session of 2025 contrasted with a broader market drop, leaving the shares little changed by the handover itself. Over Buffett’s tenure, Berkshire has outpaced the S&P 500 by a wide margin, but its sheer size makes finding needle-moving deals tougher.

Before the next session, traders will look for demand around BRK.B near the $500 mark, a round-number level many investors track. Any sharp early move would likely reflect positioning rather than a sudden change in Berkshire’s underlying businesses.

Abel’s first major public checkpoint is Berkshire’s annual shareholder meeting in Omaha on May 2, where investors will look for clues on how he frames the company’s priorities. The meeting has historically been the company’s most important stage for discussing strategy.

Beyond Berkshire-specific questions, investors will watch early-2026 economic data and Federal Reserve signaling for the rate path. That matters because Berkshire’s insurance operations and cash-heavy balance sheet can benefit when short-term returns rise.

Stock Market Today

  • ASX Penny Stocks: Audinate Group, Alcidion Group, and Austin Engineering Highlighted
    May 19, 2026, 10:46 PM EDT. The Australian stock market faces uncertainty due to high U.S. bond yields and inflation concerns. Investors eye penny stocks-smaller companies with growth potential at lower prices. Audinate Group (A$191.43M market cap) is unprofitable but debt-free, showing strong assets over liabilities and a 14.5% expected revenue growth. Alcidion Group (A$147.72M) is debt-free, profitable with recent net income of A$1.33 million, and forecasted earnings growth of 28%, boosted by a strategic acquisition in healthcare software. Austin Engineering (A$115.28M) specializes in mining equipment manufacturing. These companies highlight different paths to stability and growth amid broader market volatility.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Previous Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop